APA (7th ed.) Citation

Shao, Y., Yang, X., Yu, J., Wang, X., Wang, J., Liu, M., . . . Xun, J. (2026). Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial. Infectious Diseases & Therapy, 15(1), 165. https://doi.org/10.1007/s40121-025-01262-8

Chicago Style (17th ed.) Citation

Shao, Yueming, et al. "Bone Mineral Density Changes in People with HIV Who Had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial." Infectious Diseases & Therapy 15, no. 1 (2026): 165. https://doi.org/10.1007/s40121-025-01262-8.

MLA (9th ed.) Citation

Shao, Yueming, et al. "Bone Mineral Density Changes in People with HIV Who Had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial." Infectious Diseases & Therapy, vol. 15, no. 1, 2026, p. 165, https://doi.org/10.1007/s40121-025-01262-8.